Show simple item record

dc.contributor.authorRonald F van Vollenhoven
dc.contributor.authorLaurent Arnaud
dc.contributor.authorMarta Mosca
dc.contributor.authorNathalie Costedoat-Chalumeau
dc.contributor.authorElisabet Svenungsson
dc.contributor.authorDaniel J Wallace
dc.contributor.authorJudith A James
dc.contributor.authorKenneth Kalunian
dc.contributor.authorSusan Manzi
dc.contributor.authorMichelle A Petri
dc.contributor.authorJill Buyon
dc.contributor.authorRosalind Ramsey-Goldman
dc.contributor.authorIan N Bruce
dc.contributor.authorGuillermo Ruiz-Irastorza
dc.contributor.authorEllen M Ginzler
dc.contributor.authorManuel Francisco Ugarte-Gil
dc.contributor.authorBernardo A Pons-Estel
dc.contributor.authorJuanita Romero-Diaz
dc.contributor.authorSang-Cheol Bae
dc.contributor.authorAnisur Rahman
dc.contributor.authorPaul R Fortin
dc.contributor.authorDafna D Gladman
dc.contributor.authorAndreas Jönsen
dc.contributor.authorMurat Inanc
dc.contributor.authorDiane L Kamen
dc.contributor.authorSøren Jacobsen
dc.contributor.authorJorge Sanchez-Guerrero
dc.contributor.authorÉvelyne Vinet
dc.contributor.authorMurray Urowitz
dc.contributor.authorDavid Isenberg
dc.contributor.authorSasha Bernatsky
dc.contributor.authorJohn Reynolds
dc.contributor.authorEric Morand
dc.contributor.authorVernon Farewell
dc.contributor.authorClaudia Elera-Fitzcarrald
dc.contributor.authorCristina Reátegui-Sokolova
dc.contributor.authorAlexandre Voskuyl
dc.contributor.authorAnca D Askanase
dc.contributor.authorJohn Hanly
dc.contributor.authorAnselm Mak
dc.contributor.authorSung Sam Lim
dc.contributor.authorChristine Peschken
dc.contributor.authorGraciela S. Alarcon
dc.contributor.authorJoanna Leong
dc.contributor.authorBhushan Dharmadhikari
dc.contributor.authorNien Yee Kow
dc.contributor.authorCinthia Aranow
dc.contributor.authorMary Ann Dooley
dc.contributor.authorMike Cheung
dc.contributor.otherDepartment of Rheumatology and Clinical Immunology, Amsterdam University Medical Center, Amsterdam, The Netherlands
dc.contributor.other1 Service de rhumatologie, Hôpitaux Universitaires de Strasbourg, Laboratoire d`Immuno Rhumatologie Moléculaire, INSERM UMR_S1109, Strasbourg, France
dc.contributor.other1 Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
dc.contributor.otherCochin Hospital, Paris, France
dc.contributor.otherKarolinska Institutet, Karolinska University Hospital, Rheumatology Unit, Department of Medicine, Solna, Stockholm, Sweden
dc.contributor.otherRheumatology, Cedars-Sinai Medical Center, West Hollywood, California, USA
dc.contributor.otherArthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA
dc.contributor.other9University of California, San Diego, La Jolla, United States of America
dc.contributor.otherAllegheny Health Network, Pittsburgh, Pennsylvania, USA
dc.contributor.otherDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
dc.contributor.otherRheumatology, NYU Langone Health, New York City, New York, USA
dc.contributor.otherDepartment of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
dc.contributor.otherKellgren Centre for Rheumatology, Manchester University Hospitals NHS Trust, Manchester, UK
dc.contributor.otherAutoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain
dc.contributor.otherMedicine, SUNY Downstate Medical Center, New York City, New York, USA
dc.contributor.otherGrupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Cientifica del Sur, Lima, Peru
dc.contributor.other5Rheumatology, Grupo Oroño – Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina
dc.contributor.otherImmunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Ciudad de Mexico, Mexico
dc.contributor.other28 Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea (the Republic of)
dc.contributor.otherMaternal and Child Health Division, International Centre for Diarrhoeal Disease Research Bangladesh, Dhaka, Dhaka District, Bangladesh
dc.contributor.otherDivision of Rheumatology, CHU de Québec, Universite Laval, Quebec City, Quebec, Canada
dc.contributor.otherKrembil-Gladman Psoriatic Arthritis Research Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada
dc.contributor.otherDepartment of Rheumatology, Lund University Department of Clinical Sciences Lund, Lund, Sweden
dc.contributor.otherDivision of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Fatih, Turkey
dc.contributor.otherMedical University of South Carolina, Charleston, South Carolina, USA
dc.contributor.otherDepartment of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
dc.contributor.otherMount Sinai Hospital and University Health Network, Toronto, Ontario, Canada
dc.contributor.otherMcGill University, Divisions of Rheumatology and Clinical Epidemiology, Montreal, Canada
dc.contributor.otherSchroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, Ontario, Canada
dc.contributor.otherCentre for Rheumatology, Department of Medicine, University College London, London, UK
dc.contributor.otherDivisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada
dc.contributor.other1 Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia
dc.contributor.other1Department of Medicine, School of Clinical Sciences at MH, Monash University, Australia, Australia
dc.contributor.other1Queen Elizabeth II Health Sciences Center and Dalhousie University, Rheumatology/Medicine, Halifax, Nova Scotia, Canada
dc.contributor.otherHospital Nacional Guillermo Almenara Irigoyen, Reumatologia, Lima, Peru
dc.contributor.otherRheumatology Department, Hospital Nacional Guillermo Almenara Irigoyen, EsSaalud, Lima, Peru
dc.contributor.otherVUmc, Rheumatology, Amsterdam, Netherlands
dc.contributor.otherDepartment of Medicine, Columbia University Irving Medical Center, New York, New York, USA
dc.contributor.other1Queen Elizabeth II Health Sciences Center and Dalhousie University, Rheumatology/Medicine, Halifax, Nova Scotia, Canada
dc.contributor.otherDivision of Rheumatology, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
dc.contributor.other3Department of Medicine, Division of Rheumatology, Emory University School of Medicine, USA
dc.contributor.otherUniversity of Manitoba, Winnipeg, Manitoba, Canada
dc.contributor.otherThe University of Alabama, Birmingham, USA, School of Medicine, Birmingham, United States of America
dc.contributor.otherDepartment of Medicine, Changi General Hospital, Singapore
dc.contributor.otherDepartment of Physiology, National University of Singapore, Singapore, Singapore
dc.contributor.otherYong Loo Lin School of Medicine, National University of Singapore, Singapore
dc.contributor.otherFeinstein Institute for Medical Research, Manhasset, New York, USA
dc.contributor.otherThurston Arthritis Research Centre, University of North Carolina System, Chapel Hill, North Carolina, USA
dc.contributor.otherDepartment of Psychology, Faculty of Arts and Social Sciences, National University of Singapore, Singapore
dc.date.accessioned2025-10-09T05:21:29Z
dc.date.available2025-10-09T05:21:29Z
dc.date.issued01-May-2021
dc.identifier.urihttps://lupus.bmj.com/content/8/1/e000590.full
dc.identifier.urihttp://digilib.fisipol.ugm.ac.id/repo/handle/15717717/40976
dc.description.abstractObjective In systemic lupus erythematosus (SLE), disease activity and glucocorticoid (GC) exposure are known to contribute to irreversible organ damage. We aimed to examine the association between GC exposure and organ damage occurrence.Methods We conducted a literature search (PubMed (Medline), Embase and Cochrane January 1966–October 2021). We identified original longitudinal observational studies reporting GC exposure as the proportion of users and/or GC use with dose information as well as the occurrence of new major organ damage as defined in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. Meta-regression analyses were performed. Reviews, case-reports and studies with <5 years of follow-up, <50 patients, different outcomes and special populations were excluded.Results We selected 49 articles including 16 224 patients, 14 755 (90.9%) female with a mean age and disease duration of 35.1 years and of 37.1 months. The mean follow-up time was 104.9 months. For individual damage items, the average daily GC dose was associated with the occurrence of overall cardiovascular events and with osteoporosis with fractures. A higher average cumulative dose adjusted (or not)/number of follow-up years and a higher proportion of patients on GC were associated with the occurrence of osteonecrosis.Conclusions We confirm associations of GC use with three specific damage items. In treating patients with SLE, our aim should be to maximise the efficacy of GC and to minimise their harms.
dc.language.isoEN
dc.publisherBMJ Publishing Group
dc.subject.lccImmunologic diseases. Allergy
dc.titleImpact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies
dc.typeArticle
dc.description.doi10.1136/lupus-2021-000590
dc.title.journalLupus Science and Medicine
dc.identifier.e-issn2053-8790
dc.identifier.oaioai:doaj.org/journal:d0efe4f35013426eb5c96e31ad0e293f
dc.journal.infoVolume 8, Issue 1


This item appears in the following Collection(s)

Show simple item record